SUNNYVALE, Calif., Nov. 18, 2014 /PRNewswire/ -- Accuray
Incorporated (Nasdaq: ARAY) announced today that the first
CyberKnife® System in Manhattan is now treating patients at
Winthrop University Hospital's
NYCyberKnife Center. Winthrop's decision to install the latest
generation CyberKnife M6™ System reinforces its growing reputation
as a dedicated radiosurgery device that delivers extremely precise
full-body treatments while maximizing patients' quality of life
during and after treatment.
The CyberKnife M6 System's true robotic mobility enables it to
deliver radiation beams from a wide range of angles around the
body, precisely targeting tumors while avoiding healthy
tissue. It can be used to treat tumors anywhere in the body,
including the prostate, lung, brain, spine, liver,
pancreas and kidney. The treatment – which delivers high
doses of radiation to tumors with extreme accuracy – may offer hope
to patients who have inoperable or surgically complex tumors, or
who may prefer a clinically effective, non-surgical option.
The CyberKnife System's ability to automatically stay on target
despite patient and tumor motion is what truly differentiates it
from other forms of radiation therapy systems. It automatically
follows the tumor throughout the treatment process, intelligently
delivering radiation with sub-millimeter precision. This unique,
dynamic motion compensation feature enables clinicians to
precisely maximize dose, minimize side effects and maximize
patient comfort.
Quotes
Joshua H. Levine, president and
chief executive officer of Accuray: "The CyberKnife System is a
transformative innovation, changing the face of cancer treatment
and enabling clinicians to help their patients live longer, better
lives. We're honored that Winthrop selected our system and want to
congratulate the team as they expand their significant clinical
expertise to treating patients in Manhattan with the CyberKnife
System."
Jonathan Haas, MD, chief,
Division of Radiation Oncology at Winthrop-University Hospital:
"The Winthrop team is excited to be the first center in
Manhattan to offer patients
requiring radiation therapy the option to receive treatment with
the CyberKnife System. We saw the considerable benefits the system
has provided to our patients in Mineola, so when considering alternatives for
our new location, it was an easy choice. We selected the CyberKnife
M6 System because it includes the features and precision of the
previous model, with the potential to provide faster treatment
times and expand access to more patients."
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company
that develops,
manufactures and sells precise, innovative tumor treatment
solutions that set the standard of care with the aim of helping
patients live longer, better lives. The company's leading-edge
technologies deliver the full range of radiation therapy and
radiosurgery treatments. For more information, please visit
www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to adoption and acceptance of
the company's products, clinical experience, clinical applications,
clinical results, patient outcomes and Accuray's leadership
position in radiation oncology innovation and technologies.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from
expectations, including but not limited to the risks detailed under
the heading "Risk Factors" in the company's report on Form 10-K,
filed on August 29, 2014, the
company's report on Form 10-Q, filed on November 7, 2014, and the company's other filings
with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Video -
http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/The-CyberKnife(R)-System-Animation-10-9-14.mp4
Photo - http://photos.prnewswire.com/prnh/20141117/159151
SOURCE Accuray Incorporated